CO2019006320A2 - Moléculas biespecíficas de unión al receptor 2 del ligando inductor de apoptosis relacionado con tnf y anti-cadherina 17 para el tratamiento del cáncer - Google Patents

Moléculas biespecíficas de unión al receptor 2 del ligando inductor de apoptosis relacionado con tnf y anti-cadherina 17 para el tratamiento del cáncer

Info

Publication number
CO2019006320A2
CO2019006320A2 CONC2019/0006320A CO2019006320A CO2019006320A2 CO 2019006320 A2 CO2019006320 A2 CO 2019006320A2 CO 2019006320 A CO2019006320 A CO 2019006320A CO 2019006320 A2 CO2019006320 A2 CO 2019006320A2
Authority
CO
Colombia
Prior art keywords
tnf
molecules
inducing ligand
related apoptosis
receptor binding
Prior art date
Application number
CONC2019/0006320A
Other languages
English (en)
Inventor
Klaus-Peter Kuenkele
Timothy Fenn
Juan Manuel Garcia-Martinez
Jason Ho
Christian Koessl
Saurabh Sen
Vladimir Voynov
Andreas Wernitznig
Ertan Eryilmaz
Rajkumar Ganesan
Abdulsalam Shaaban
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO2019006320A2 publication Critical patent/CO2019006320A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

La presente invención se refiere a moléculas de fijación que se fijan específicamente al receptor 2 del ligando inductor de la apoptosis relacionado con TNF (TRAILR2) y a cadherina 17 (CDH17) y su uso medicinal, composiciones farmacéuticas que las comprenden y métodos para usarlas como agentes para el tratamiento y/o la prevención del cáncer
CONC2019/0006320A 2017-02-14 2019-06-17 Moléculas biespecíficas de unión al receptor 2 del ligando inductor de apoptosis relacionado con tnf y anti-cadherina 17 para el tratamiento del cáncer CO2019006320A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17155973.5A EP3360898A1 (en) 2017-02-14 2017-02-14 Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
PCT/EP2017/084002 WO2018115231A2 (en) 2016-12-22 2017-12-21 Binding molecules for the treatment of cancer

Publications (1)

Publication Number Publication Date
CO2019006320A2 true CO2019006320A2 (es) 2019-06-28

Family

ID=58043942

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0006320A CO2019006320A2 (es) 2017-02-14 2019-06-17 Moléculas biespecíficas de unión al receptor 2 del ligando inductor de apoptosis relacionado con tnf y anti-cadherina 17 para el tratamiento del cáncer

Country Status (15)

Country Link
US (2) US10858438B2 (es)
EP (2) EP3360898A1 (es)
JP (1) JP7196076B2 (es)
KR (1) KR102651761B1 (es)
CN (1) CN110582513B (es)
AU (1) AU2017384687A1 (es)
BR (1) BR112019011750A2 (es)
CA (1) CA3046591A1 (es)
CO (1) CO2019006320A2 (es)
EA (1) EA201991480A1 (es)
MA (1) MA47121A (es)
MX (1) MX2019007511A (es)
PE (1) PE20191251A1 (es)
TW (1) TWI790219B (es)
WO (1) WO2018115231A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
AU2021276332A1 (en) * 2020-05-19 2022-11-17 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
JP2024503508A (ja) 2021-01-15 2024-01-25 シージェン インコーポレイテッド 免疫調節性抗体－薬物コンジュゲート
EP4288109A1 (en) 2021-02-03 2023-12-13 Seagen Inc. Immunostimulatory compounds and conjugates
EP4352218A1 (en) * 2021-06-07 2024-04-17 Flagship Pioneering Innovations VII, LLC Compositions and methods for targeted delivery of therapeutic agents
CN113512117B (zh) * 2021-07-12 2023-08-22 武汉麦考津生物科技有限公司 一种可结合cd206的抗体及其应用
WO2023015169A1 (en) * 2021-08-02 2023-02-09 Tavotek Biotech (Suzhou) Ltd Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
WO2023023677A1 (en) * 2021-08-20 2023-02-23 University Of Virginia Patent Foundation Strategy for highly superior dr5 activation including in tumors and cancers
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
US20240052065A1 (en) 2022-07-15 2024-02-15 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2024030577A1 (en) 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
WO2024081930A1 (en) * 2022-10-14 2024-04-18 Flagship Pioneering Innovations Vii, Llc Compositions and methods for targeted delivery of therapeutic agents
CN115785269B (zh) * 2022-11-01 2023-09-22 四川大学 抗pd-l1的抗体及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US168A (en) 1837-04-17 Improvement in fire-arms
US5731A (en) 1848-08-22 Elisha k
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DK1087013T3 (da) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobuliner uden lette kæder
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
ES2138662T3 (es) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc Produccion de fragmentos de anticuerpos.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP0981548A4 (en) 1997-04-30 2005-11-23 Enzon Inc SINGLE CHAIN PROTEINS FIXING ANTIGENS CAPABLE OF GLYCOSYLATION, PRODUCTION AND USES THEREOF
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002056910A1 (en) 2001-01-17 2002-07-25 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2004003019A2 (en) 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
NZ532881A (en) * 2001-12-20 2008-04-30 Human Genome Sciences Inc Antibodies that immunospecifically bind to trail receptors
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
PL1639011T3 (pl) 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060228352A1 (en) 2005-02-24 2006-10-12 Schoenberger Stephen P TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
TWI428444B (zh) 2005-10-12 2014-03-01 Morphosys Ag 由全長人類ＨｕＣＡＬ ＧＯＬＤ-衍生之對人類ＣＤ３８有特異性之治療抗體之產生及鑑定
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2421898B1 (en) * 2009-04-20 2016-03-16 Oxford BioTherapeutics Ltd Antibodies specific to cadherin-17
CA2773515C (en) * 2009-09-29 2015-04-28 Roche Glycart Ag Bispecific death receptor agonistic antibodies
KR20130138802A (ko) * 2010-10-20 2013-12-19 옥스포드 바이오테라퓨틱스 리미티드 항체
US20130025987A1 (en) 2011-07-18 2013-01-31 David Batterbee Methods and apparatus for controlling a fluid damper
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
NO2776305T3 (es) 2014-04-23 2018-01-27
WO2016024195A1 (en) 2014-08-12 2016-02-18 Novartis Ag Anti-cdh6 antibody drug conjugates
EA201791050A1 (ru) 2014-11-14 2017-09-29 Новартис Аг Конъюгаты антител и лекарственных средств
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
US10501552B2 (en) 2015-01-26 2019-12-10 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
DK3458478T3 (da) 2016-05-18 2021-03-22 Boehringer Ingelheim Int Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer

Also Published As

Publication number Publication date
CA3046591A1 (en) 2018-06-28
US11851495B2 (en) 2023-12-26
JP7196076B2 (ja) 2022-12-26
US20180179287A1 (en) 2018-06-28
WO2018115231A3 (en) 2018-08-02
KR102651761B1 (ko) 2024-03-26
CN110582513B (zh) 2023-11-14
TWI790219B (zh) 2023-01-21
TW201835102A (zh) 2018-10-01
WO2018115231A2 (en) 2018-06-28
EP3360898A1 (en) 2018-08-15
MA47121A (fr) 2019-10-30
CN110582513A (zh) 2019-12-17
US10858438B2 (en) 2020-12-08
JP2020501586A (ja) 2020-01-23
BR112019011750A2 (pt) 2019-10-29
MX2019007511A (es) 2019-09-04
US20210095038A1 (en) 2021-04-01
KR20190099223A (ko) 2019-08-26
EP3559040A2 (en) 2019-10-30
EA201991480A1 (ru) 2020-01-15
PE20191251A1 (es) 2019-09-18
AU2017384687A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
CO2019006320A2 (es) Moléculas biespecíficas de unión al receptor 2 del ligando inductor de apoptosis relacionado con tnf y anti-cadherina 17 para el tratamiento del cáncer
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
EA201892241A1 (ru) Диарильные макроциклы в качестве модуляторов протеинкиназ
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2014002257A1 (es) Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
CO2017000065A2 (es) Indoles funcionalizados y sustituidos como agentes anti-cáncer
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2019014199A (es) Tratamiento de combinacion antineoplasico.
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
BR112015023074A2 (pt) agentes de ligação-met e uso dos mesmos
ECSP14014778A (es) Composiciones derivadas de la quitosana
CL2017002405A1 (es) Compuestos bicíclicos fusionados, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades o desordenes relacionados con el fxr.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
MX2017009608A (es) Compuestos anticancerigenos.
ECSP18041731A (es) Derivados Novedosos de Diamino Piridina
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
AR110568A1 (es) Moléculas de fijación para el tratamiento del cáncer
CL2019001684A1 (es) Moléculas de fijación para el tratamiento del cáncer.